Swedish cancer diagnostics company BiBBInstruments AB (Spotlight: BIBB) said on Wednesday that it received additional fourth-quarter orders from its US distributor TaeWoong Medical USA worth USD31,840 (SEK 300k).
The orders form part of a targeted US launch initiated in the autumn.
EndoDrill GI is a powered biopsy instrument for endoscopic ultrasound that holds US Food and Drug Administration clearance and CE marking. The system received US 510(k) clearance in 2023 and CE marking in 2024, is in clinical use in both regions, and began its US launch in autumn 2025.
TaeWoong Medical USA is seeking to establish regular use at major reference hospitals to underpin a nationwide launch in 2026, while BiBBInstruments AB is also in discussions with potential European distribution partners with the aim of a 2026 market entry.
BiBBInstruments AB said fourth-quarter order value to date exceeds third-quarter sales by more than 170%.
AstraZeneca secures US Breakthrough status for Enhertu in early breast cancer
GSK agrees US pricing framework to expand access to respiratory medicines
ECO Animal Health Group secures EU approval for ECOVAXXIN MS
Century Health partnerss with Tessel Biosciences to advance early drug development in COPD
Curasight reports first patient dosed in Phase 1 uTREAT trial in brain cancer
BioNTech completes acquisition of CureVac
Clywedog Therapeutics activates all clinical centres and patient dosing in balomenib Phase 1b study
BiBBInstruments reports additional US orders during targeted EndoDrill GI launch
GENinCode expands Mexico presence with CARDIO inCode-Score distribution agreement
Sanofi's efdoralprin alfa receives EU orphan designation for AATD-related emphysema
Anixa Biosciences transfers breast cancer vaccine IND from Cleveland Clinic
Physiomics secures follow-on UK contract for Phase 2 study support
RedHill Biopharma reports positive opaganib data in venetoclax-resistant CLL
Qlife's Egoo Health platform selected for major AI-driven diabetes and MASLD project in China